Patent Application
20240033260
Myopia is a worldwide public health issue, and is highly prevalent in Hong Kong [1-3]. It is predicted that around half and one-tenth of the world's population will become myopic and highly myopic respectively by year 2025 [4, 5]. Highly myopic individual has excessive eyeball growth and therefore a higher risk of sight-threatening complications, including glaucoma, cataract, retinal detachment, and other stretch-induced degenerative changes of retinal pigment epithelium, choroid and sclera [6]. In China, about 36.5% fourth graders and 65.3% eighth graders have poor eyesight [7]. Prevention of childhood myopia progression is exceedingly important. In view of that, President Xi Jinping has stated the need to control myopia in China for a better children's eye health and bright future [8]. A national scheme, jointly issued by Ministry of Education, the National Health Commission and six other Departments of the state, has been announced to reduce the myopia rate among 6 years old to 3%, among primary school pupils to below 38%, junior high school pupils to below 60% and senior high school students to 70% by year 2030 [9].
Despite decades of scientific research in the causes of myopia, its exact etiology remains unclear. Environmental pressures, such as the rigorous education system in highly urbanized cities like Hong Kong that demand heavy near work from intensive reading papers or electronic screens, are attributed to the high prevalence of myopia. Electronic device usage is inevitable in children in Hong Kong nowadays. Furthermore, the prevalence of myopia in Chinese is the highest among all populations in the world. [4,5] It is notable that children start to develop myopia as early as age of four, with fast progression from age eight to twelve, and then a slower progression until around age eighteen. Myopia, once developed and progressed, is irreversible. Therefore, timely measures to prevent myopia onset and its progression since childhood is exceedingly crucial [7].
Different interventions have been attempted to reduce myopic progression, such as increasing outdoor time [10-12]. Other methods include optical methods, e.g., bifocal/progressive spectacles [13-16], orthokeratology [17, 18], defocus spectacles and contact lens [19].
Pharmacological methods, mainly atropine eye drops, have been shown to have some effects [20-24]. A Cochrane database systemic review concluded that anti-muscarinic agents including atropine eye drop were the most effective anti-myopia treatment [25]. A meta-analysis of 16 different interventions also showed that atropine eye drops conferred the best efficacy among all myopia prevention methods [26]. The American Academy of Ophthalmology also recommended its use [27].
Atropine is a nonselective muscarinic receptor antagonist with many postulated mechanisms for its anti-myopia actions, including its biochemical effects on the retina and sclera for eyeball remodeling [28, 29]. Atropine in the Treatment of Myopia (ATOM 1) study at a daily regimen of 1% atropine eye drops reduced myopia progression by 77% when compared with placebo eye drops treatment over a 2-year period [21]. However, side effects included cycloplegia and pupil dilatation resulting in blurred near vision and photophobia. The subsequent ATOM 2 study from the same study group showed that lower concentrations of topical atropine (0.5%, 0.1% and 0.01%) one drop nightly over two years were effective in reducing annual myopia progression to −0.3+/−0.6 D, −0.38+/−0.6 D, and −0.49+/−0.63 D, respectively [22]. Because of low side effects and less rebound after stopping the treatment, 0.01% atropine was recommended as the optimal concentration [20]. The use of a low-concentration atropine is further supported by other groups from the United States and Taiwan [31-34].
Unfortunately, after the onset of myopia in children, its progression is very difficult to control. Currently, there is no effective intervention for inhibiting or delaying the onset of myopia. In a retrospective study of 24 children, a composition comprising 0.025% atropine was administered to myopic children nightly versus 26 children in the control group without any intervention, in which there was a significantly lower proportion of onset of myopia along the one-year follow-up period in the treatment group versus the control group (21% vs 54%) [35]. This study was however limited by its retrospective nature and small sample size [35].
Therefore, there remains a need for a safe and effective treatment to inhibit or delay the onset of myopia, particularly childhood myopia.
The present invention relates to a nonselective muscarinic receptor antagonist, atropine, and compositions comprising atropine. In certain embodiments, the concentration of atropine in the composition can be about 0.001% to about 0.5%, preferably about 0.05% to about 0.01%. The present invention further pertains to novel methods of inhibiting or delaying the onset of myopia, particularly in children. In certain embodiments, the children are less than about 12, about 11, about 10, about 9, about 8, about 7, about 6, about 5, or about 4 years old. In certain embodiments, administration of atropine compositions can occur for at least about six months, about one year, about two years, about three years, about four years, about five years, about six years, about seven years, or about eight years.
In certain embodiments, the Spherical Equivalent (SE) of the eye is about +1.00 D to greater than −0.5 D before administration of the composition. In some embodiments, the SE is measured by cycloplegic autorefraction. In certain embodiments, the subject has no astigmatism or has astigmatism of less than about 1.00 D. In certain embodiments, the subject has no anisometropia or has anisometropia of less than about 2.00 D. In certain embodiments, the subject has at least one myopic parent. The myopic subject can have an SE of less than or equal to −3.00 D.
In certain embodiments, the onset of myopia is inhibited or delayed. In certain embodiments, the onset of myopia is delayed for at least about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 12 months, about 18 months, about two years, about three years, about 4 years, about five years, about six years, about 7 years, or about eight years.
As used herein, the singular forms “a,” “an,” and “the” are intended to include the plural 30 forms as well, unless the context clearly indicates otherwise. Further, to the extent that the terms “including,” “includes,” “having,” “has,” “with,” or variants thereof are used in either the detailed description and/or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising.” The transitional terms/phrases (and any grammatical variations thereof) “comprising,” “comprises,” “comprise,” include the phrases “consisting essentially of,” “consists essentially of” “consisting,” and “consists.”
The phrases “consisting essentially of” or “consists essentially of” indicate that the claim encompasses embodiments containing the specified materials or steps and those that do not materially affect the basic and novel characteristic(s) of the claim.
The term “about” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. Where particular values are described in the application and claims, unless otherwise stated the term “about” meaning within an acceptable error range for the particular value should be assumed.
In the present disclosure, ranges are stated in shorthand, to avoid having to set out at length and describe each and every value within the range. Any appropriate value within the range can be selected, where appropriate, as the upper value, lower value, or the terminus of the range. For example, a range of 1-10 represents the terminal values of 1 and 10, as well as the intermediate values of 2, 3, 4, 5, 6, 7, 8, 9, and all intermediate ranges encompassed within 1-10, such as 2-5, 2-8, and 7-10. Also, when ranges are used herein, combinations and sub-combinations of ranges (e.g., subranges within the disclosed range) and specific embodiments therein are intended to be explicitly included.
In certain embodiments of the invention a subject is a mammal. Non-limiting examples of a mammal treatable according to the methods of the current invention include mouse, rat, dog, guinea pig, cow, horse, cat, rabbit, pig, monkey, ape, chimpanzee, and human. Additional examples of mammals treatable with the methods of the current invention are well known to a person of ordinary skill in the art and such embodiments are within the purview of the current invention.
For the purposes of this invention the terms “treatment, treating, treat” or equivalents of these terms refer to healing, alleviating, relieving, altering, remedying, ameliorating, improving, or affecting the condition or the symptoms of a subject suffering with a disease or condition, for example, a myopia. The subject to be treated can be suffering from or at risk of developing the disorder or condition, for example, myopia. When provided therapeutically, the compound can be provided before the onset of a symptom. The therapeutic administration of the substance serves to attenuate any actual symptom.
For the purposes of this invention, the terms “preventing, preventive, prophylactic” or equivalents of these terms are indicate that the compounds of the subject invention are provided in advance of any disease symptoms and are a separate aspect of the invention (i.e., an aspect of the invention that is distinct from aspects related to the terms “treatment, treating, treat” or equivalents of these terms which refer to healing, alleviating, relieving, altering, remedying, ameliorating, improving, or affecting the condition or the symptoms of a subject suffering from myopia). The prophylactic administration of the compounds of the subject invention serves to prevent, reduce the likelihood, or attenuate one or more subsequent symptoms or condition.
By “therapeutically effective dose,” “therapeutically effective amount”, or “effective amount” is intended to be an amount of a compounds of the subject invention disclosed herein that, when administered to a subject, decreases the number or severity of symptoms or inhibits or eliminates the progression or initiation of myopia or reduces any increase in symptoms, or improve the clinical course of the disease as compared to untreated subjects. “Positive therapeutic response” refers to, for example, improving the condition of at least one of the symptoms of myopia.
An effective amount of the therapeutic agent is determined based on the intended goal. The term “unit dose” refers to a physically discrete unit suitable for use in a subject, each unit containing a predetermined quantity of the therapeutic composition calculated to produce the desired response in association with its administration, i.e., the appropriate route and treatment regimen. The quantity to be administered, both according to number of treatments and unit dose, depends on the subject to be treated, the state of the subject and the protection desired. Precise amounts of the therapeutic composition also depend on the judgment of the practitioner and are peculiar to each individual. Generally, the dosage of the compounds of the subject invention will vary depending upon such factors as the patient's age, weight, height, sex, general medical condition and previous medical history.
In some embodiments of the invention, the method comprises administration of multiple doses of the compounds of the subject invention. The method may comprise administration of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000 or more therapeutically effective doses of a composition comprising the compounds of the subject invention as described herein. In some embodiments, doses are administered over the course of 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 14 days, 21 days, 30 days, 2 months, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, or more than 10 years. The frequency and duration of administration of multiple doses of the compositions is such as to inhibit or delay the initiation of myopia. Moreover, treatment of a subject with a therapeutically effective amount of the compounds of the invention can include a single treatment or can include a series of treatments. It will also be appreciated that the effective dosage of a compound used for treatment may increase or decrease over the course of a particular treatment. Changes in dosage may result and become apparent from the results of diagnostic methods for detecting myopia known in the art and described herein. In some embodiments of the invention, the method comprises administration of the compounds at a single time per day or several times per day, including but not limiting to 2 times per day, 3 times per day, and 4 times per day.
As used herein, the term “myopia” refers to a subject having at least one eye with an Spherical Equivalence (SE) value less than or equal to −0.5 D, such as, for example, −1.0 D, −2.0 D.
As used herein, the term “pre-myopia” refers to a subject having at least one eye with an SE value of about −0.49 D to about 1.00 D.
As used herein, The term “mild myopia” refers to a subject having at least one eye with an SE value of about −0.50 D to −1.50 D.
As used herein, The term “moderate myopia” refers to a subject having at least one eye with an SE value of about −3.00 D to −6.00 D.
The term “high myopia” refers to a subject having at least one eye with an SE value of about −6.0 D or less, such as, for example −7.0 D or −8.0 D. As used herein, the term “drop” refers to a unit of measure of volume, which is equal to the amount dispensed as one drop from a dropper or drip chamber. In certain embodiments, a drop can contain about 20 μl to about 100 μl, about 30 μl to 70 μl, or about 50 μl of liquid.
As used herein, the phrase “accommodation amplitude”, refers to the ability of the eye to focus on near objects. A decrease in accommodation amplitude may reduce near vision such that subjects affected need bifocal or progressive glasses to read or see close objects.
In preferred embodiments, the compositions and methods according to the subject invention utilize atropine, including, for example, atropine salts (e.g., atropine sulfate).
All medications can be manufactured by Aseptic Innovative Medicine Co., Ltd. (Taoyuan City, Taiwan) The drugs can be a clear, colorless, and sterile solution. The solutions can be provided in 0.5 mL low density polyethylene (LDPE) ampoules, however, other storage and/or administration containers can be envisioned. The compositions can be stored below 25° C. and avoid direct light.
Atropine may be added to compositions at concentrations of about 0.0001 to about 5% by weight (wt %), preferably about 0.01 to about 0.5 wt %, and most preferably about 0.025% to about wt %. In another embodiment, atropine can be in combination with an acceptable carrier and/or excipient, in that atropine may be presented at concentrations of about 0.0001 to about 5% (v/v), preferably, about 0.01 to about 0.5% (v/v), more preferably, about 0.025 to about 0.05% (v/v), or, most preferably, greater than 0.025 to about 0.05% (v/v). In certain embodiments, atropine can be present in the composition are a concentration of about 0.010%, about 0.011%, about 0.012%, about 0.013%, about 0.014%, about 0.015%, about 0.016%, about 0.017%, about about 0.019%, about 0.020%, about 0.021%, about 0.022%, about 0.023%, about 0.024%, about 0.025%, about 0.026%, about 0.027%, about 0.028%, about 0.029%, about 0.03%, about about 0.032%, about 0.033%, about 0.034%, about 0.035%, about 0.036%, about 0.037%, about 0.038%, about 0.039%, about 0.04%, about 0.041%, about 0.042%, about 0.043%, about about 0.045%, about 0.046%, about 0.047%, about 0.048%, about 0.049%, about 0.05%, about 0.051%, about 0.05%, about 0.052%, about 0.053%, about 0.053%, about 0.054%, about about 0.056%, about 0.057%, about 0.058%, about 0.059%, or about 0.06%.
In certain embodiments, the compositions are preferably administered to the eye, including, for example, ophthalmic administration, conjunctival administration, intracorneal administration, intraocular administration, intravitreal administration, or retrobulbar administration.
In one embodiment, the orally consumable product is a, syrup, emulsion, or liquid suspension containing a desired orally deliverable substance.
The subject composition can further comprise one or more pharmaceutically acceptable carriers, and/or excipients, and can be formulated into preparations, for example, semi-solid, liquid, or gaseous forms, such as ointments, solutions, suppositories, and injections.
The term “pharmaceutically acceptable” as used herein means compatible with the other ingredients of a pharmaceutical composition and not deleterious to the recipient thereof.
Carriers and/or excipients according the subject invention can include any and all solvents, diluents, buffers (such as, e.g., neutral buffered saline, phosphate buffered saline, or optionally Tris-HCl, acetate or phosphate buffers), oil-in-water or water-in-oil emulsions, aqueous compositions with or without inclusion of organic co-solvents suitable for use, e.g., IV solubilizers (e.g., Polysorbate 65, Polysorbate 80), colloids, dispersion media, vehicles, fillers, chelating agents (e.g., EDTA or glutathione), amino acids (e.g., glycine), proteins, disintegrants, binders, lubricants, wetting agents, emulsifiers, sweeteners, colorants, flavorings, aromatizers, thickeners (e.g. carbomer, gelatin, or sodium alginate), coatings, preservatives (e.g., Thimerosal, benzyl alcohol, polyquaterium), antioxidants (e.g., ascorbic acid, sodium metabisulfite), tonicity controlling agents, absorption delaying agents, adjuvants, bulking agents (e.g., lactose, mannitol) and the like. The use of carriers and/or excipients in the field of drugs and supplements is well known. Except for any conventional media or agent that is incompatible with the target health-promoting substance or with the composition, carrier or excipient use in the subject compositions may be contemplated. In certain embodiments, the compositions can comprise a polymer, such as, for example, Hypromellose (HPMC)-606, a salt, such as, for example, sodium phosphate monobasic, sodium chloride, sodium borate, and an acid, such as, for example, boric acid or hydrochloric acid.
In certain embodiments, medications can be formulated as:
In one embodiment, the compositions of the subject invention can be formulated for administration via injection, for example, as a solution or suspension. The solution or suspension can comprise suitable non-toxic, parenterally-acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, non-irritant, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid. One illustrative example of a carrier for intravenous use includes a mixture of 10% USP ethanol, 40% USP propylene glycol or polyethylene glycol 600 and the balance USP Water for Injection (WFI). Other illustrative carriers for intravenous use include 10% USP ethanol and USP WFI; 0.01-0.1% triethanolamine in USP WFI; or 0.01-0.2% dipalmitoyl diphosphatidylcholine in USP WFI; and 1-10% squalene or parenteral vegetable oil-in-water emulsion. Water or saline solutions and aqueous dextrose and glycerol solutions may be preferably employed as carriers, particularly for injectable solutions. Illustrative examples of carriers for subcutaneous or intramuscular use include phosphate buffered saline (PBS) solution, 5% dextrose in WFI and 0.01-0.1% triethanolamine in 5% dextrose or 0.9% sodium chloride in USP WFI, or a 1 to 2 or 1 to 4 mixture of 10% USP ethanol, 40% propylene glycol and the balance an acceptable isotonic solution such as 5% dextrose or 0.9% sodium chloride; or 0.01-0.2% dipalmitoyl diphosphatidylcholine in USP WFI and 1 to 10% squalene or parenteral vegetable oil-in-water emulsions.
In certain embodiments, methods of administering to a subject a composition comprising atropine are provided. In certain embodiments, the subjects are not myopic before the atropine treatment; including, for example, the subject has a positive SE value or a negative value of 0 to −0.5 D, such as, for example −0.3 D. In certain embodiments, the subject has an SE value of about +1.00 D to −0.49 D, about 0.75 D to about −0.49 D, or about +1.00 D to about 0 D.
In certain embodiments, the subject can be of any age. In preferred embodiments, the subject is at least about 4 years old. In preferred embodiments, the subject is about 4 to about 9 years old. In some cases, the subject has no history of ophthalmic diseases other than refractive errors. In some cases, the subject has an astigmatism of less than about 1.00 D, anisometropia of less than about 2.0 D, or any combination thereof. In some cases, the subject has at least one parent who is myopic, including, for example, at least one parent whose SE is less than or equal to −3.00 D.
In certain embodiments, at least one method can be used to determine the ocular health of a subjects before, during, or after administration of the compositions comprising atropine. Non-limiting exemplary methods include determining the best corrected visual acuity for near and distant (EDTRS) charts, near aided visual acuity, ocular alignment using a covered and uncovered test, extraocular movement, pupil size, intraocular pressure by non-contact tonometry (NCT), accommodation amplitude by measurement of the Royal Air Force near point rule, and/or cycloplegic autorefraction. In some cases, two, three or all of the aforementioned methods are performed to evaluate the patient's ocular health, including assessing the degree of myopia by determining SE values.
In certain embodiments, effects of the compositions on the subject can be determined. Atropine's effect on preventing or delaying the onset of myopia can be assessed by examining the eye during periodic visits during treatment and, optionally, after treatment and determining the timing when the patient first becomes myopic, i.e., when the patient's SE of the subject is about −0.5 D. The timing is then compared with the timing of the onset of myopia in a control group that does not receive an administration of a composition comprising atropine but instead receives vehicle placebo eye drops. The control subject is typically of a similar age and ethnic background to the patient treated with atropine. The subjects in the control group may also have an ocular health status comparable to that of the individuals in the treatment group before the beginning of atropine treatment. In preferred embodiments, the individuals from the control group are pre-myopic and between ages of about 4 and about 9.
In certain embodiments, the subject can be monitored for ocular health at the beginning of the treatment and during periodic examinations during and/or after treatment. The subjects can be monitored, such as, for example, every one, two, three, four, five, six, seven, or eight months during and/or after the treatment period. In some cases, patients are examined for ocular health, including the degree of myopia (e.g., axial distance and/or SE value) every about 4 to about 6 months after treatment begins.
In certain embodiments, the compositions comprising atropine can be administered to a subject to inhibit or delay the onset of myopia by administration to the eye. In some embodiments, doses are administered over the course of about 30 days, about 2 months, about 3 months, about 6 months, about 9 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, about 10 years, or more than 10 years.
In some embodiments, treating the patient with the composition disclosed herein can delay the onset of myopia for at least about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 12 months, about 18 months, about two years, about three years, about 4 years, about five years, about six years, about 7 years, or about eight years as compared to controls. For purpose of this disclosure, controls refer to individuals who are not treated with the atropine composition disclosed herein. In preferred embodiments, the individuals in the control group are from the same age group and at the same pre-myopic as the individuals who are treated with the compositions disclosed herein.
In certain embodiments, the subject composition can be delivered to the subject via a topical route, formulated as solutions, suspensions, emulsions, gels, ointments, pastes, etc. In preferred embodiments, the composition can be a liquid solution to be applied to the eye of a subject (i.e., ophthalmic administration). In certain embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or drops can be administered to a subject. In certain embodiments, one drop can have a volume of about 20 μL to about 100 μL, about 25 μL to about 75 μL, or about 50 μL.
In certain embodiments, the composition can be administered at any time in a day. In certain embodiments, the composition can be administered to a subject once, twice, thrice or more times per day. In certain embodiments, the composition can be administered every two days, every three days, or every four days. In certain embodiments, each administration can occur at a consistent time period, volume, and concentration. In certain embodiments, the time period between administrations can increase or decrease during the treatment period. In certain embodiments, the volume of the administrations can increase or decrease during the treatment period. In certain embodiments, the concentration of the compositions administered can increase or decrease during the treatment period.
In certain embodiments, the treatment period can occur for at least about one year, about two years, about 3 years, about four years, about five years, about six years, about seven years, about eight years, or about ten years. In certain embodiments, the composition can be administered 6 months to about 1 year, 18 months to 2 years, 1 year to 2 years, 16 to 32 months, 24 to 48 months, 32 to 48 months, 32 to 52 months, 48 to 52 months, 48 to 64 months, 52 to 64 months, 52 to 72 months, 64 to 72 months, 64 to 80 months, 72 to 80 months, 72 to 88 months, 80 to 88 months, 80 to 96 months, 88 to 96 months, and 96 to 104 months. Suitable periods of administration also include 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 24, 28, 30, 32, 36, 42, 48, and 56 months. Generally administration of the composition should be continued as long as clinically significant myopia inhibition or delaying of myopia is observed.
In some embodiments, administration of an atropine composition is not continuous and can be stopped for one or more periods of time, followed by one or more periods of time where administration resumes. Suitable periods where administration stops include 5 to 9 months, 5 to 16 months, 9 to 16 months, 16 to 24 months, 16 to 32 months, 24 to 32 months, 24 to 48 months, 32 to 48 months, 32 to 52 months, 48 to 52 months, 48 to 64 months, 52 to 64 months, 52 to 72 months, 64 to 72 months, 64 to 80 months, 72 to 80 months, 72 to 88 months, 80 to 88 months, 80 to 96 months, 88 to 96 months, and 96 to 100 months. Suitable periods where administration stops also include 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 24, 25, 30, 32, 35, 40, 45, 48 52, 55, 60, 64, 65, 68, 70, 72, 75, 80, 85, 88 90, 95, 96, and 100 months.
In certain embodiments, atropine can be used in combination with other active agents known to be useful for inhibiting or delaying the onset of myopia.
In certain embodiments, the mean change in refraction following the start of administration of the composition can be reduced by at least about 10%, about 20%, about 30%, about 31%, about 35%, about 36%, about 37%, about 40%, about 50%, about 60%, about 70%, about 75%, about 78%, about 79%, or about 80% over a period of at least about two weeks, about one month, about two months, about six months, about one year, about two years, about three years, about four years, about five years, about six years, about seven years, or about eight years from the initiation of the treatment as compared to controls.
In some embodiments, the mean change in of axial length following the start of administration of the composition can be reduced by at least about 5%, about 10%, about 15%, about 17%, about 18%, about 20%, or about 25%, about 30%, about 31%, about 35%, about 36%, about 37%, or about 40% over a period of at least about two weeks, about one month, about two months, about six months, about one year, about two years, about three years, about four years, about five years, about six years, about seven years, or about eight years from the initiation of the treatment as compared to controls.
In certain embodiments, the incidence of myopia following the start of administration of the composition can be reduced by at least about 10%, about 20%, about 25%, about 26%, about 30%, about 35%, about 36%, about 37%, about 40%, about 50%, about 60%, about 63%, about 64% about 70%, or about 75% over a period of at least about two weeks, about one month, about two months, about six months, about one year, about two years, about three years, about four years, about five years, about six years, about seven years, or about eight years from the initiation of the treatment as compared to controls.
In certain embodiments, changes in accommodation amplitude during the treatment period can be small, in which accommodation amplitude in a subject treated with atropine and a subject in a placebo group can be in a range of about 1 D to about 20 D or about 5 D to about 15 D in which the accommodation amplitude varies by less than about 6 D, about 5 D, about 4 D, about 3 D, about 2 D, about 1 D, about 0.5 D, about 0.3 D, about 0.2 D, or about 0.1 D between a subject treated with atropine and a subject treated with a placebo.
In certain embodiments, changes in mesopic pupil size during the treatment period can be small, in which mesopic pupil size in a subject treated with atropine and a subject in a placebo group can be in a range of about 1 mm to about 10 mm or about 5 mm to about 8 mm in which the mesopic pupil sizes varies by less than about 3 mm, about 2 mm, about 1 mm, about 0.5 mm, about mm, about 0.2 mm, or about 0.1 mm between a subject treated with atropine and a subject treated with a placebo.
In certain embodiments, changes in photopic pupil size during the treatment period can be small, in which photopic pupil size in a subject treated with atropine and a subject in a placebo group can be in a range of about 1 mm to about 10 mm or about 5 mm to about 8 mm in which the photopic pupil sizes varies by less than about 2 mm, about 1 mm, about 0.5 mm, about 0.3 mm, about 0.2 mm, or about 0.1 mm between a subject treated with atropine and a subject treated with a placebo.
In certain embodiments, changes in distant visual acuity during the treatment period can be small, in which distant visual acuity in a subject treated with atropine and a subject in a placebo group can be in a range of about −0.01 to about −0.05 logMAR for a subject treated with atropine compositions or about −0.01 to about −0.06 logMAR for a subject treated with a placebo.
In certain embodiments, changes in near visual acuity can be small, in which near visual acuity in a subject treated with atropine and a subject in a placebo group can be in a range of about 0.001% to about 0.1% or about 0.01% to about 0.07%.
The study is a double blinded randomized clinical trial. Eligible children will be randomized into groups: treatment group: 0.01% atropine both eyes once daily; treatment group: atropine both eyes once daily; and a placebo group: eye drops both eyes once daily.
For the first two years, all the groups remained unchanged.
After two years, children from the placebo group will remain in the placebo group until they have onset of myopia with a spherical equivalence (SE)≤−0.5 Diopter (D). That is, they can be switched to the treatment group administering 0.05% atropine once they have onset of myopia (SE≤−0.5 D). Children from treatment group administering 0.01% atropine will remain in the group until they have onset of myopia with SE≤−0.5 D. That is, they can be switched to treatment group administering 0.05% atropine year once they have onset of myopia (SE≤−0.5 D). Treatment group administering 0.05% atropine will remain in the same group throughout the whole study period.
Eligible subjects are children aged 4 to 9 with a SE of 0 D to +1.0 D, astigmatism of <1.00 D; anisometropia of <2.0 D; at least one parent whose SE is ≤−3.00 D; and informed parental consent. Subjects are excluded if he/she has ophthalmic diseases other than refractive errors, or previous use of treatment of atropine, or an allergy or intolerance to atropine, and/or an inability to attend regular follow up assessment.
The age limit of 4-9 years old is set due to the reasons below. Children younger than 4 years old can be very difficult for accurate cycloplegic examination and biometry measurement. Also, early onset myopes tend to be a fast progressor. Therefore we do not include children older than 9 years.
Compared to having both non-myopic parents, having one moderate myopic parent confer a 2-fold increased risk, and having both highly myopic parents confers a 12-fold increased risk, for children to develop myopia. Therefore, children with at least one parent moderate myopic will be recruited.
To calculate the required number of study subjects, we took the estimated myopia onset rate for 0.05%, and 0.01% atropine and placebo groups to be and 6.6%, 14.6%, 20% respectively. The 0.05% atropine group should have the smallest number of myopic onset, thus a minimum of 5 to 10 myopia children should be observed. To detect a difference among treatment groups, a sample size of 375 subjects (125 per group) could achieve 90% power at a 0.05 significance level. By factoring in an attrition rate of 20%, a sample size of 474 subjects (158 per group) would be needed.
This is a double-blinded randomized control trial that lasts for four years. All participating children will be randomized into one of the following groups in 1:1:1 ratio for treatment group: atropine both eyes once daily; treatment group: 0.05% atropine both eyes once daily; and a placebo group: eye drops both eyes once daily.
Children are offered photochromatic glasses if they experienced glare or their parents are worried about excessive light exposure, or progressive glasses if children experienced difficulty with near vision. The treatment can be continued for four years.
This is a double-blinded randomized control trial, last for four years.
All participating children will be randomized into one of the following groups in 1:1:1 ratio:
Aim:
Block randomization will be used to assign consecutive cases into either treatment arm in the proposed RCT. The block size could be 4, 6 or 8 (the actual block size will be kept confidential to all of the investigators and participating staffs except for the statistician who design the randomization strategies). Since age has been shown to be a major factor that associated with the onset of myopia, we will randomize eligible subjects in 8 strata separately (i.e. 1) age 4-6 female in +1.00 D≤SE≤+0.50 D, 2) age 4-6 male in +1.00 D≤SE<+0.50 D, 3) age 4-6 female in +0.50 D≤SE≤0.00 D, 4) age 4-6 male in +0.50 D≤SE≤0.00 D, 5) age 7-9 female in +1.00 D≤SE≤+0.50 D, 6) age 7-9 male in +1.00 D≤SE<+0.50 D, 7) age 7-9 female in +0.50 D≤SE≤0.00 D, and 8) age 7-9 male in +0.50 D≤SE≤0.00 D). Randomization table will be generated and kept confidential by a statistician independently. Only the staff who is designated as the person to obtain the randomization code can get access to the table and assign treatment arms for each study subject. The investigator, the patient and the staff who conducts the follow-up examinations will be kept unaware of the randomization information. In the study design, we have taken into account the possible effect of covariates on the estimated sample size.
The assignment of groups will not be disclosed to the subjects (including their parents) and investigators. All types of eye drops (atropine 0.01%, 0.05% and lubricant) will be contained in the same type of bottle. All the optometrists responsible for assessing the study outcomes will be blinded to the treatment given to each of the children. The statistician will also be blinded to the assigned treatment for each child.
Examination as in Visit 1
Cycloplegic refraction at visit 2 will be used as baseline 2 for future comparison of myopia progression if any, as hyperopic shift may occur after commencing atropine eye drops. Children will be offered photochromatic glasses if they experience glare or their parents are worried about excessive light exposure, or progressive glasses if children experience difficulty with near vision.
Visits 3-8 (Treatment Follow-Up Visits, Every 4 months)
The placebo group will be switched to 0.05% atropine group during the third year when SE≤−0.5 D. Subject will be kept in the placebo group when SE remains >−0.5 D. 0.01% atropine group will be switched to 0.05% atropine group during the third year when SE≤−0.5 D. Subject will be kept in the 0.01% atropine group when SE remains >−0.5 D.
The children are advised to come back for assessment when any problems with the treatments arise, such as deterioration of vision, treatment complications. The children will have detailed examination. New prescription will be given when indicated. When there is severe side effect associated with the treatment, the treatment will be stopped. The children will be asked to come back at the original schedule after the unscheduled visit
Visit 1 Day 0 (Baseline 1)
Visit 2 Week 2 (Baseline 2+assessment of tolerance)
Visit 3 Month 4 (Treatment follow-up visits)
Visit 4 Month 8 (Treatment follow-up visits)
Visit 5 Month 12 (Treatment follow-up visits)
Visit 6 Month 16 (Treatment follow-up visits)
Visit 7 Month 20 (Treatment follow-up visits)
Visit 8 Month 24 (Treatment follow-up visits)
Visit 9 Month 30 (Treatment follow-up visits)
Visit 10 Month 36 (Treatment follow-up visits)
Visit 11 Month 42 (Treatment follow-up visits)
Visit 12 Month 48 (Treatment follow-up visits)
Myopia is defined as a spherical equivalent refractive error of at least −0.50 D, based on the Refractive Error Study in Children. The Proportion of onset of myopia and proportion of fast myopia progressor in each group can be determined to establish efficacy. Myopic progression can be measured by change in spherical equivalent refraction (SER). Cycloplegic refraction is assessed by using an auto-refractometer. Eyeball growth is measured by change in axial length, using the IOL master.
Intention-to-treat analysis will be employed. The proportion of onset of myopia and proportion of fast myopic progressor in each treatment group are the primary outcome measures. Change from baseline SER and axial length in the treatment group and the control group are the secondary outcome measures. These will be analyzed by multiple regression models. Baseline measurements, treatment group, parental history of myopia, age, and their interaction will be used as factors in the model. The analysis of safety measures made on categorical or frequency scales will be based on chi-square statistics. Analysis of Variance (ANOVA) model will be built up to identify the treatment effect, period effect, carry-over effect and their interaction
Adverse Effects & Patient Withdrawal/Exit from Study
Atropine is known to occasionally can cause side-effects. Systemic effects include, for example, tachycardia, respiratory stress, allergic dermatitis. Ocular effects include increase in intraocular pressure (TOP), phototoxicity and early presbyopia.
These potential side-effects can be closely monitored, so can be the physical integrity of the cornea, lens and retina. They can be examined with direct examination, serial photography and specular microscopy. IOP is measured with non-contact tonometry (NCT) and/or applanation. The data then can be used to project the proportion of the patient population (4-9 year-olds) that may become sensitive to topical atropine.
All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.
Following are examples that illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.
The mean and standard deviation of change in SE for 1 year in 429 children: −0.55±0.60 D, −0.38±0.53, and −0.12±0.48 D, for placebo, 0.01%, and 0.05% atropine daily, respectively (
In our series of atropine studies, the 0.05% atropine was well tolerated by al. the children in pupil dilation, accommodation loss, near vision, and best-corrected distant vision. The vision-related quality of life was not affected. Changes in accommodation amplitude were small. Accommodation amplitude in both 0.05% and 0:01% atropine groups were comparable with the placebo group, 13.35±2.91, 13.63±2.61 and 13.35±2.74 D in the 0.05% atropine group, and the 0.01% atropine group, and the placebo group, respectively (Table 1). The changes in pupil size was comparable in both 0.05% and 0.01% atropine. Mesopic pupil sizes were 6.37±0.73, 6.32±0.82 and 6.57±0.79 mm in 0.05% atropine, 0.01% atropine and placebo groups, respectively; while photopic pupil sizes were 3.53±0.59, 3.65±0.70, and 3.69±0.66 mm, in 0.05% atropine, 0.01% atropine, and placebo groups, respectively. Both distant BCVA and near visual acuity in both 0.05% and 0.01% atropine were not affected significantly. Distant visual acuity: 0.03±0.09, 0.02±0.08, and 0.03±0.08, for 0,05% and 0.01% atropine and placebo group, respectively, while near visual acuity: 0.05±0.11, 0.03±0.10, and 0.02±0.09, for 0.05% and 0.01% atropine and placebo groups, respectively. The 0.05% atropine composition is safe and more effective than 0.01% atropine composition in inhibiting the onset of myopia.
It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims. In addition, any elements or limitations of any invention or embodiment thereof disclosed herein can be combined with any and/or all other elements or limitations (individually or in any combination) or any other invention or embodiment thereof disclosed herein, and all such combinations are contemplated with the scope of the invention without limitation thereto.
